• Family Mediterranean fever 
To content

Family Mediterranean fever 

SOVREMENNAYA PEDIATRIYA.2015.4(68):91-95; doi 10.15574/SP.2015.68.91 

Family Mediterranean fever 

Chernishova L. I., Volokha A. P., Stepanovskyi Yu. S., Mostovenko R. V,. Yanushevskaya D. V., Ginka O. V., Boiko Ya. E.

P.L. Shupik National Medical Academy of Postgraduate Education, Kiev, Ukraine

The National Children's Specialized Hospital «OKHMATDET», Kiev, Ukraine

West Ukrainian Pediatric Immunology Center 

Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disorder characterised by acute attacks of fever and serosal inflammation. Familial Mediterranean Fever primarily affects Jewish, Armenian, Turkish, and Arab populations. The disease is accompanied by a marked decrease in quality of life due to the effects of attacks and subclinical inflammation in the attack*free periods. Untreated or inadequately treated patients run the risk of amyloidosis, which is an important cause of morbidity and mortality. 

Key words: Familial Mediterranean fever, serositis, colchicine. 


1. Gattorno M, Galeotti C, Caorsi R, Hentgen V. 2012. Autoinflammatory syndromes. EULAR Textbook on Rheumatic Diseases. Bijlsma J. W. J. ed.: 372—89.

2. Ben-Chetrit E, Levy M. 1998. Familial Mediterranean fever. Lancet. 351: 659—64.

3. Ben-Chetrit E, Ozdogan H. 2008. Non_response to colchicine in FMF-definition, causes and suggested solutions. Clin Exp Rheumatol. 26: 49—51.

4. Cantarini L, Rigante D, Brizi MG et al. 2012. Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med. 44: 664—73.

5. Zemer D, Pras M, Sohar E et al. 1986. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 314: 1001—1005.

6. Dinarello CA, Wolff SM, Goldfinger SE et al. 1974. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med. 291: 934—7.

7. Livneh A, Langevitz P, Zemer D et al. 1997. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 40: 1879—1885.

8. Kotone-Miyahara Y, Takaori-Kondo A, Fukunaga K et al. 2004. E148Q/M694I mutation in 3 Japanese patients with familial Mediterranean fever. Int J Hematol. 79(3): 235—7. http://dx.doi.org/10.1532/IJH97.03119; PMid:15168590

9. Erken E, Ozer HT, Bozkurt B et al. 2008. Early suppression of familial Mediterranean fever attacks by single medium dose methylprednisolone infusion. Joint Bone Spine. 75: 370—2.

10. Konstantopoulos K, Kanta A, Deltas C et al. 2003. Familial Mediterranean fever associated pyrin mutations in Greece. Ann Rheum Dis. 62(5): 479—81. http://dx.doi.org/10.1136/ard.62.5.479; PMid:12695165 PMCid:PMC1754548

11. Samuels J, Aksentijevich I, Torosyan Y et al. 1998. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore). 77: 268—97.

12. Ben-Chetrit E, Touitou I. 2009. Familial mediterranean Fever in the world. Arthritis Rheum. 61: 1447—53.

13. La Regina MNG, Diaco M, Procopio A et al. 2004. Familial Mediterranean fever is no longer a rare disease in Italy. Eur J Hum Genet. 12(2): 85—6.

14. Sohar E, Gafni J, Pras M, Heller H. 1967. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 43: 227—53.

15. French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet. 1997. 17: 25—31.

16. Gedalia A. 2000. Familial Mediterranean fever. Nelson Textbook of Pediatrics / Behrman R, Kliegman RM, Jenson HB, eds. 16th ed. Philadelphia, WB Saunders: 727.

17. Yalcinkaya F, Cakar N, Misirlioglu M et al. 2000. Genotype-phenotype correlation in a large group of Turkish patients with familial mediterranean fever: evidence for mutation_independent amyloidosis. Rheumatology (Oxford). 39: 67—72.

18. Masters SL, Simon A, Aksentijevich I et al. 2009. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 27(1): 621—68. http://dx.doi.org/10.1146/annurev.immunol.25.022106.141627; PMid:19302049 PMCid:PMC2996236

19. Meinzer U, Quartier P, Alexandra JF et al. 2011. Interleukin_1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 41: 265—71.

20. Zemer D, Livneh A, Danon YL et al. 1991. Long_term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 34: 973—7.

21. Majeed HA, Barakat M. 1989. Familial Mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases. Eur J Pediatr. 148: 636—41.

22. Aksentijevich I, Torosyan Y, Samuels J et al. 1999. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am J Hum Genet. 64: 949—62.

23. Onen F. 2006. Familial Mediterranean fever. Rheumatol Int. 26: 489—96.

24. Ozgocmen S, Akgul O. 2011. Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature. Mod Rheumatol. 21: 684—90.

25. Ozkurede VU, Franchi L. 2012. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes inautoinflammatory syndromes. Clin Exp Immunol. 167: 382—90.

26. Toplak N, Dolezalova P, Constantin T et al. 2010. Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey. Pediatr Rheumatol Online J. 8: 29.

27. Livneh A, Langevitz P, Zemer D et al. 1996. The changing face of familial Mediterranean fever. Semin Arthritis Rheum. 26: 612—27.

28. Geha RS, Notarangelo L D, Casanova J-L et al. 2007. The International Union of Immunological Societies (IUIS) Primary Immunodeficiency Diseases (PID) Classification Committee. J Allergy Clin Immunol. 120(4): 776—794.

29. Touitou I. 2001. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 9: 473—83.